Taya Lewis
Family · Cincinnati, OHNPI 1235778481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,210 and has fallen 66.3% since, to $408 in 2025. Among family clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$615
- Novo Nordisk$533
- Lilly USA, LLC$507
- Pfizer$283
- Boehringer Ingelheim$252
- GSK$238
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,913100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $615 |
| Novo Nordisk | 34 | $533 |
| Lilly USA, LLC | 39 | $507 |
| Pfizer | 21 | $283 |
| Boehringer Ingelheim | 15 | $252 |
| GSK | 25 | $238 |
| AstraZeneca | 8 | $217 |
| Medtronic | 6 | $145 |
| Dexcom, Inc. | 7 | $117 |
| Amgen | 6 | $100 |
| Merck | 5 | $96 |
| Novartis | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Johnson & Johnson | 4 | $62 |
| Daiichi Sankyo Inc. | 4 | $57 |
| Exact Sciences | 3 | $55 |
| BETA Bionics, Inc. | 2 | $44 |
| Biogen | 2 | $43 |
| Corcept Therapeutics | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Antares Pharma, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Eisai Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
How this compares
$3,913 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 25 | $26,604 |
| EliquisApixaban | 29 | $22,399 |
| OzempicSemaglutide | 13 | $14,326 |
| FarxigaDapagliflozin Propanediol | 21 | $14,142 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $6,269 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $6,181 |
| Bupropion XlBupropion Hcl | 38 | $5,800 |
| Gabapentin | 133 | $1,711 |
| Atorvastatin Calcium | 263 | $1,672 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $1,584 |
| Levothyroxine Sodium | 147 | $1,371 |
| Omeprazole | 89 | $1,102 |
| Lidocaine | 14 | $992 |
| Pantoprazole Sodium | 60 | $619 |
| FenofibrateFenofibrate Nanocrystallized | 20 | $591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $507 | $26,60425 claims |
| PfizerEliquis | $283 | $22,39929 claims |
| Novo NordiskOzempic | $533 | $14,32613 claims |
| AstraZenecaFarxiga | $217 | $14,14221 claims |
| AbbVieSynthroid | $615 | $41712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Cincinnati
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Lindsey SpencerCincinnati$53K
- Bria BarjucaCincinnati$38K
- Jillian CowanCincinnati$20K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.